

used to treat diseases associated with increased cell survival, or the inhibition of apoptosis, including cancers (e.g. follicular lymphomas, carcinomas with p53 mutations, and hormone dependent tumours, such as breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer), autoimmune disorders (e.g. systemic lupus erythematosus related glomerulonephritis, rheumatoid arthritis), viral infections (e.g. herpes viruses, pox viruses and adenoviruses), inflammation, graft vs host disease, acute graft rejection and chronic graft rejection. Antagonists can be used to treat diseases associated with increased apoptosis including AIDS, neurodegenerative disorders (e.g. Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury (e.g. that caused by myocardial infarction, stroke, and reperfusion injury), toxin-induced liver disease (e.g. that caused by alcohol), septic shock, cachexia, anorexia, inflammatory diseases and stress response related diseases, such as psoriasis and septicemia. The products can also be used for detection and diagnosis.

Sequence 655 AA:

Query Match	100.0%	Score	3456	DB	2	Length	655
Local Similarity	100.0%	Pred. No.	1..3e-274	Matches	65	Conservative	0
Matches	65	Mismatches	0	Indels	0	Gaps	0
1	MGTSSSSSTLASSRRIARRATATMAGSLLGILGRISTTAQPEQKASNLIGTYRHDA	1	MGTSSSSSTLASSRRIARRATATMAGSLLGILGRISTTAQPEQKASNLIGTYRHDA	60			
61	TQQLITCDKCPAGTYVSEHCTNTSLRVCCSPVGPFTRHENGIEKCHDSCQCPWPMIEK	61	TQQLITCDKCPAGTYVSEHCTNTSLRVCCSPVGPFTRHENGIEKCHDSCQCPWPMIEK	12			
121	LPCALTDRECBTPGFMQSNATCAPIHTCPVPGVKGCTETEDVRCLQCARGTGFSDV	121	LPCALTDRECBTPGFMQSNATCAPIHTCPVPGVKGCTETEDVRCLQCARGTGFSDV	186			
61	TQQLITCDKCPAGTYVSEHCTNTSLRVCCSPVGPFTRHENGIEKCHDSCQCPWPMIEK	61	TQQLITCDKCPAGTYVSEHCTNTSLRVCCSPVGPFTRHENGIEKCHDSCQCPWPMIEK	12			
181	SSVMCKKAYTDCLSQNLVWIKPDKETDNVCGTLPSPSSSTSPSPGAIFFPBMHETE	181	SSVMCKKAYTDCLSQNLVWIKPDKETDNVCGTLPSPSSSTSPSPGAIFFPBMHETE	240			
241	VPSSTVYPKGMNSTESSSASTPKVLISSQGTVPDNTSSARGKDENVKTPNLQVNH	241	VPSSTVYPKGMNSTESSSASTPKVLISSQGTVPDNTSSARGKDENVKTPNLQVNH	300			
301	QOGPHHRHHLKULPSMEATGKKSSTPIKGPKRGRPQRQNLHKGFDINELHPLMWVFLIL	301	QOGPHHRHHLKULPSMEATGKKSSTPIKGPKRGRPQRQNLHKGFDINELHPLMWVFLIL	360			
361	VLVWIVVCSIRKSSRTKKGDRQDSAIVEGALKKUSMTPTONREKMYIYNGHGIDLK	361	VLVWIVVCSIRKSSRTKKGDRQDSAIVEGALKKUSMTPTONREKMYIYNGHGIDLK	420			
361	VLVWIVVCSIRKSSRTKKGDRQDSAIVEGALKKUSMTPTONREKMYIYNGHGIDLK	361	VLVWIVVCSIRKSSRTKKGDRQDSAIVEGALKKUSMTPTONREKMYIYNGHGIDLK	420			
421	LVAQVGSKWPKDIYQFLCNASEREPFAFSGYTADHERAALQHTIREPAASTQALIS	421	LVAQVGSKWPKDIYQFLCNASEREPFAFSGYTADHERAALQHTIREPAASTQALIS	480			
481	ALQHRRDUDWVEKRGLEMEDDTQLETDKLAULPMSDPSPLSPSPSPNAKLNSALLTVEP	481	ALQHRRDUDWVEKRGLEMEDDTQLETDKLAULPMSDPSPLSPSPSPNAKLNSALLTVEP	540			
541	SPQDKNKGFFVDESEPLARCDSTSSGSSALSRSGSFITEKKDVKLQFLDQDQPLTF	541	SPQDKNKGFFVDESEPLARCDSTSSGSSALSRSGSFITEKKDVKLQFLDQDQPLTF	600			
601	DDMLHFLNPRLPEVIEETPQAEDKLDRFLFELCVKQSEASQITLDVSHLFDL	601	DDMLHFLNPRLPEVIEETPQAEDKLDRFLFELCVKQSEASQITLDVSHLFDL	655			
601	DDMLHFLNPRLPEVIEETPQAEDKLDRFLFELCVKQSEASQITLDVSHLFDL	601	DDMLHFLNPRLPEVIEETPQAEDKLDRFLFELCVKQSEASQITLDVSHLFDL	655			

ID	AAV1693	standard; protein; 6
XX		
AC	AY41693;	
XX		
DT	07-DEC-1999	(first entry)
XX		
DE	Human PRO868	protein sequence
XX		
KW	Human; PRO; EST; expressed sequence	
KW	probe; blood coagulation disorder	
KW	secreted protein; transmembrane	
XX		
OS	Homo sapiens.	
XX		
PN	W09946281-12.	
XX		
PD	16-SEP-1999.	
XX		
PR	08-MAR-1999;	99WO-US005028.
XX		
PR	10-MAR-1998;	98US-0077450P.
PR	11-MAR-1998;	98US-0077632P.
PR	11-MAR-1998;	98US-0077414P.
PR	11-MAR-1998;	98US-0077649P.
PR	12-MAR-1998;	98US-0077791P.
PR	13-MAR-1998;	98US-0078004P.
PR	17-MAR-1998;	98US-00040220.
PR	20-MAR-1998;	98US-0078816P.
PR	20-MAR-1998;	98US-0078916P.
PR	20-MAR-1998;	98US-0078936P.
PR	25-MAR-1998;	98US-0078939P.
PR	26-MAR-1998;	98US-0079294P.
PR	27-MAR-1998;	98US-0079656P.
PR	27-MAR-1998;	98US-0079663P.
PR	27-MAR-1998;	98US-0079689P.
PR	27-MAR-1998;	98US-0079778P.
PR	30-MAR-1998;	98US-0079820P.
PR	30-MAR-1998;	98US-0079933P.
PR	31-MAR-1998;	98US-0080105P.
PR	31-MAR-1998;	98US-0080107P.
PR	31-MAR-1998;	98US-008165P.
PR	01-APR-1998;	98US-008194P.
PR	01-APR-1998;	98US-0082027P.
PR	01-APR-1998;	98US-008328P.
PR	01-APR-1998;	98US-008333P.
PR	08-APR-1998;	98US-008334P.
PR	08-APR-1998;	98US-0081049P.
PR	08-APR-1998;	98US-0081070P.
PR	09-APR-1998;	98US-0081071P.
PR	09-APR-1998;	98US-0081195P.
PR	09-APR-1998;	98US-0081203P.
PR	15-APR-1998;	98US-0081229P.
PR	15-APR-1998;	98US-0081817P.
PR	15-APR-1998;	98US-0081838P.
PR	15-APR-1998;	98US-0081952P.
PR	21-APR-1998;	98US-0081955P.
PR	21-APR-1998;	98US-0082266P.
PR	21-APR-1998;	98US-0083336P.
PR	22-APR-1998;	98US-0082566P.
PR	22-APR-1998;	98US-0082700P.
PR	22-APR-1998;	98US-0082704P.
PR	23-APR-1998;	98US-0082804P.
PR	23-APR-1998;	98US-0082767P.
PR	27-APR-1998;	98US-0082266P.
PR	28-APR-1998;	98US-0083322P.
PR	29-APR-1998;	98US-0083392P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.
PR	29-APR-1998;	98US-0083500P.
PR	29-APR-1998;	98US-0083545P.